Evaluation of Vaginal PAMG-1 Detection by PartoSure Test in Preterm Delivery Threat in Actual Clinical Situation: Randomized Controlled Trial

Pregnancy Preterm Clinical Trial

— PARTO-MAP  

Official title:

Evaluation of Vaginal PAMG-1 Detection by PartoSure Test in Preterm Delivery Threat in Actual Clinical Situation: Randomized Controlled Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03675061
• Other study ID #: 29BRC17.0203 - PARTO-MAP
• Status: Completed
• Phase: N/A
• Start date: December 11, 2018
• Est. completion date: February 23, 2021

Study information

• Verified date: April 2021
• Source: University Hospital, Brest
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Prematurity is defined as birth before 37 weeks of amenorrhea. It is the leading cause of perinatal morbidity and mortality. It is estimated that premature births to 15 million worldwide in 2010, including 60,000 children in France (7,4% of births) and 12000, born before 32 weeks of amenorrhea (term defining great prematurity). More than half of these births follow spontaneous work.

Before 34 weeks of amenorrhea, prematurity requires specific maternal-fetal management centered primarily on antenatal corticosteroid treatment for fetal maturation including 2 intramuscular injections at 24 hour intervals. This cure can only be done once and its benefit is proven in the 7 (to 14) days before the birth (recommendation for the clinical practice of the French National College of Obstetricians and Gynecologists of December 2016). The single course of antenatal corticosteroids before 34 weeks of amenorrhea is associated in the neonatal period with reduction in morbidity and mortality, and in the long term with an improvement of the survival without sequelae, if the full cure is administered in the 7, to 14, days before birth. The second key element of the management of a premature delivery threats is the admission in a pediatric structure adapted to the degree of prematurity.

The care of a premature delivery threats before 34 weeks of amenorrhea care leads to hospitalization with possible transfer to a maternity of pediatric adapted level, tocolysis, a biological and bacteriological assessment, and, sometimes, other examinations and treatments.

The prediction of premature labor is a challenge. Current methods, such as vaginal examination, cervicometry and detection of fetal fibronectin, make it possible to obtain a negative predictive value (NPV) approaching 100% but a poor positive predictive value (PPV), thus 8 out of 10 patients hospitalized and treated for premature delivery threat no not give birth within 7 days, or even before 34 weeks of amenorrhea. A better prediction of preterm delivery has two benefits: administer antenatal corticosteroid therapy in high-risk patients at the right time and not treat not-at risk patients.

The PartoSure® test, which detects the placental protein vaginal alphamicroglobulin-1 (PAMG-1), has satisfactory metrological qualities according to observational studies : NPV 98% and PPV 75% of delivery within 7 days.

However this test has never been evaluated in real clinical condition. In our study, the result of the test becomes decisional for the care.

The hypothesis is that use of this test will improve the prediction of preterm delivery during a first consultation for preterm delivery threat and thus allow more frequent prenatal corticosteroid treatment in optimal period, avoiding treating non-at risk patients.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 128
• Est. completion date: February 23, 2021
• Est. primary completion date: February 23, 2021
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Major patient

• Pregnant of a singleton

• Followed at Brest hospital and resident unless 30 kms of Hospital

• Patient consultant for preterm delivery threat before 34 weeks of amenorrhea with more than 6 contractions per hour (ie 1 in 10 minutes) felt and / or sensed by external toco-ergometry associated with cervical changes objectified by a measurement of the cervix by ultrasound between 15 and 25 mm

• With capacity of a free and informed consent

• Affiliated member of the French social security system

Exclusion Criteria:

• Patient transferred for preterm delivery from a peripheral hospital center

• Patient not followed at Brest hospital

• Patient doesn't lives within 30 km of the Brest hospital

• Clinical premature rupture of membranes

• Circled patients

• Important metrorrhagia

• Cervix <15 mm

• Cervical dilatation > 3 cm

• Isolated short cervix defined by a short cervix in measurement of the cervix by ultrasound without uterine contraction felt or captured in external toco-ergometry

• Placenta previa, placenta percreta

• Multiple pregnancy

• Suspicion of chorioamnionitis

• Associated maternal-fetal pathology that may induce prematurity

• No prenatal corticosteroid treatment for this pregnancy

Related Conditions & MeSH terms

• Pregnancy Preterm
• Premature Birth

Intervention

Other:
• Current care
Tocolysis and a complete corticosteroid treatment.

Device:
• PartoSure Test negative
Biochemical test and nifedipine tocolysis, then return at home with the midwife's visit at home twice a week up to 34 weeks of amenorrhea .
• PartoSure Test positive
Biochemical test and tocolysis and a complete corticosteroid treatment. then if situation is stable, return at home with the midwife's visit at home twice a week up to 34 weeks of amenorrhea

Locations

Country	Name	City	State
France	CHRU Brest	Brest

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Brest

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Comparison of the two strategies used for patients with preterm delivery threat and intact membranes	Compare impact of experimental diagnosis strategy (binding usual diagnosis strategy and research of vaginal PAMG-1 with PartoSure® test) with usual diagnosis strategy only, in population of patients with preterm delivery threat and intact membranes, about frequency of appropriate care concerning corticosteroids cure.	7 days
Secondary	Comparison of frequency of prescription of antenatal corticosteroids by following the prescription of patients	Compare frequency of prescription adequacy of antenatal corticosteroids cure appropriate in the 14 days of inclusion between the both diagnosis strategies	14 days
Secondary	diagnosis performances	Assess diagnosis performances (NPV, PPV, Se, Sp) of PartoSure® test in actual clinical situation	7 days
Secondary	Change of care following initial care	Assess care modifications consecutive of initial care by following the numbers of hospitalisation for preterm delivery prediction	14 days
Secondary	Health strategy	Compare the differences of health expenditure cost under experimental strategy and usual strategy	14 days
Secondary	Neonatal morbidity	Compare neonatal morbidity between both group	An average of 40 weeks
Secondary	Neonatal mortality	Compare neonatal mortality between both group	An average of 40 weeks
Secondary	Level of preterm delivery prediction	Assess in the experimental group the level of preterm delivery prediction in the 7 days	7 days